<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="manner" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="3" relname="concession">The main finding of our study is that the risk of AKI rose proportionally according to the amount of pRBC and FFP transfusions in both ABO-c and ABO-i LT ,</segment>
<segment id="3" parent="1002" relname="span">but this association of pRBC and FFP transfusions with post-transplant AKI was stronger in ABO-i LT than in ABO-c LT .</segment>
<segment id="4" parent="1005" relname="joint">Given that the AKI rates increased in patients with preoperative anemia</segment>
<segment id="5" parent="1005" relname="joint">and that the influence of transfusion on AKI was more pronounced in ABO-i LT patients ,</segment>
<segment id="6" parent="1006" relname="span">any efforts</segment>
<segment id="7" parent="6" relname="purpose">to reduce perioperative transfusions may protect patients with ABO-i LT against AKI .</segment>
<segment id="8" parent="1008" relname="span">However ,</segment>
<segment id="9" parent="1009" relname="span">as our observations were from a retrospective analysis ,</segment>
<segment id="10" parent="1010" relname="span">prospective trials are required</segment>
<segment id="11" parent="10" relname="purpose">to confirm our hypothesis .</segment>
<segment id="12" parent="1012" relname="span">Patient mortality and graft survival after ABO-i LT have been reported to be comparable to ABO-c LT ,</segment>
<segment id="13" parent="1013" relname="span">although there is still concern regarding the high incidence of antibody-mediated rejection ,</segment>
<segment id="14" parent="1014" relname="span">including biliary stricture</segment>
<segment id="15" parent="14" relname="elaboration">related to a high isoagglutinin titer .</segment>
<segment id="16" parent="1015" relname="joint">This high isoagglutinin titer may provoke another major organ injury , including AKI , through an immunologic response .</segment>
<segment id="17" parent="18" relname="circumstance">As AKI affects graft outcomes and mortality after liver transplantation ,</segment>
<segment id="18" parent="1017" relname="span">it is important to elucidate modifiable risk factors of AKI in ABO-i LT .</segment>
<segment id="19" parent="1019" relname="span">The reason</segment>
<segment id="20" parent="1020" relname="span">why AKI occurs more frequently in ABO-i LT is not certain ,</segment>
<segment id="21" parent="20" relname="concession">although the high isoagglutinin titer may play a role .</segment>
<segment id="22" parent="1021" relname="joint">A high isoagglutinin titer may lead to major organ damage through possible immunologic injury .</segment>
<segment id="23" parent="1023" relname="span">In addition , the prevalent baseline metabolic alkalosis , low platelet count , and high incidence of mild arterial hypoxemia prior to transplantation surgery may contribute to the high incidence of intraoperative transfusion and low oxygen delivery to the kidney .</segment>
<segment id="24" parent="23" relname="elaboration">Furthermore , patients with ABO-i LT already receive a substantial amount of FFP transfusion for plasma exchange prior to surgery .</segment>
<segment id="25" parent="1026" relname="span">FFP has been reported to be a risk factor for AKI after surgery ,</segment>
<segment id="26" parent="25" relname="elaboration">including liver transplantation ,</segment>
<segment id="27" parent="1027" relname="span">and the risk of AKI may increase</segment>
<segment id="28" parent="27" relname="circumstance">when patients with ABO-i LT receive intraoperative FFP transfusions .</segment>
<segment id="29" parent="1030" relname="span">Furthermore , an inflammatory , allergic , and immunologic reaction</segment>
<segment id="30" parent="29" relname="elaboration">triggered by FFP transfusion may be exacerbated</segment>
<segment id="31" parent="1030" relname="circumstance">when patients receive additional intraoperative FFP .</segment>
<segment id="32" parent="1032" relname="span">Red cell transfusion is also a well-known risk factor of AKI after liver transplantation .</segment>
<segment id="33" parent="1033" relname="joint">The negative effect of pRBC transfusion is multifaceted</segment>
<segment id="34" parent="1034" relname="span">and includes a systemic inflammatory response ,</segment>
<segment id="35" parent="34" relname="elaboration">which contributes to the development of AKI after surgery .</segment>
<segment id="36" parent="1036" relname="span">A large amount of transfusion reflects excessive surgical bleeding ,</segment>
<segment id="37" parent="1037" relname="span">which leads to renal hypoperfusion and ischemia ,</segment>
<segment id="38" parent="37" relname="result">resulting in poor oxygen delivery .</segment>
<segment id="39" parent="1038" relname="joint">There was a dose â€“ response relationship between the amount of pRBC and FFP transfusion and the risk of AKI in our study .</segment>
<segment id="40" parent="1041" relname="attribution">However , it is not clear</segment>
<segment id="41" parent="1041" relname="span">why the patients</segment>
<segment id="42" parent="41" relname="elaboration">undergoing ABO-i LT were more susceptible to the deleterious effects of pRBC transfusion .</segment>
<segment id="43" parent="1042" relname="joint">Possible mechanisms include that the adverse effect of pRBC transfusion may be aggravated by a high isoagglutinin titer .</segment>
<segment id="44" parent="1046" relname="concession">Although we accounted for confounding factors through propensity-score-matching and multivariable analysis ,</segment>
<segment id="45" parent="1046" relname="span">we could not adjust the isoagglutinin titer</segment>
<segment id="46" parent="45" relname="cause">due to a lack of data .</segment>
<segment id="47" parent="1045" relname="elaboration">In addition , red cell transfusion is closely related to FFP transfusion .</segment>
<segment id="48" parent="1047" relname="joint">Cumulative FFP transfusion after preoperative plasma exchange could be the leading cause ,</segment>
<segment id="49" parent="1049" relname="span">and pRBC transfusion could be a simple association .</segment>
<segment id="50" parent="1050" relname="span">To reduce the transfusion amount in ABO-i LT ,</segment>
<segment id="51" parent="1051" relname="span">we could adopt a restrictive transfusion policy</segment>
<segment id="52" parent="51" relname="means">by decreasing the transfusion threshold .</segment>
<segment id="53" parent="54" relname="concession">Although there is no established consensus regarding intraoperative transfusion ,</segment>
<segment id="54" parent="1053" relname="span">the pRBC transfusion threshold in our institution during liver transplantation was around 20 % in hematocrit .</segment>
<segment id="55" parent="1055" relname="span">This threshold could be lowered further</segment>
<segment id="56" parent="55" relname="elaboration">depending on the baseline status of recipients or the mixed venous oxygen concentrations .</segment>
<segment id="57" parent="1057" relname="span">Red cell transfusion during surgery could possibly be reduced</segment>
<segment id="58" parent="1058" relname="same_unit">by optimizing baseline hematocrit before surgery</segment>
<segment id="59" parent="1058" relname="same_unit">through the administration of erythropoietin .</segment>
<segment id="60" parent="1061" relname="attribution">A previous randomized trial reported</segment>
<segment id="61" parent="1061" relname="span">that a preoperative single intravenous dose of erythropoietin could reduce the transfusion amount during cardiac surgery ,</segment>
<segment id="62" parent="61" relname="result">thereby reducing the incidence of postoperative AKI .</segment>
<segment id="63" parent="1063" relname="span">In addition , to reduce transfusion requirements , the intraoperative use of vasopressin was reported</segment>
<segment id="64" parent="63" relname="purpose">to reduce surgical bleeding through selective splanchnic vasoconstriction and by reducing portal blood flow .</segment>
<segment id="65" parent="1065" relname="span">The incidence of AKI in our study was within the range</segment>
<segment id="66" parent="65" relname="elaboration">reported in previous literature .</segment>
<segment id="67" parent="1066" relname="joint">The incidence of AKI in ABO-i LT was also similar to a previous study .</segment>
<segment id="68" parent="1067" relname="span">The risk factors of AKI other than ABO-i LT were mostly consistent with those of the previous literature .</segment>
<segment id="69" parent="1068" relname="joint">The preoperative hemoglobin level was independently associated with post-transplant AKI .</segment>
<segment id="70" parent="1069" relname="joint">The MELD score has been consistently reported to be a predictor of AKI .</segment>
<segment id="71" parent="1070" relname="span">Ischemic time was not identified as an independent predictor of AKI in our analysis ,</segment>
<segment id="72" parent="71" relname="elaboration">which could have been due to the relatively short ischemic time of LDLT .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1004" type="multinuc" parent="1003" relname="contrast"/>
<group id="1005" type="multinuc" parent="1004" relname="same_unit"/>
<group id="1006" type="span" parent="1004" relname="same_unit"/>
<group id="1007" type="multinuc" parent="1003" relname="contrast"/>
<group id="1008" type="span" parent="1007" relname="joint"/>
<group id="1009" type="span" parent="8" relname="manner"/>
<group id="1010" type="span" parent="9" relname="elaboration"/>
<group id="1011" type="multinuc" parent="1007" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="12" relname="concession"/>
<group id="1014" type="span" parent="13" relname="elaboration"/>
<group id="1015" type="multinuc" parent="1011" relname="joint"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="joint"/>
<group id="1018" type="multinuc" parent="1016" relname="joint"/>
<group id="1019" type="span" parent="1018" relname="joint"/>
<group id="1020" type="span" parent="19" relname="elaboration"/>
<group id="1021" type="multinuc" parent="1018" relname="joint"/>
<group id="1022" type="multinuc" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="multinuc" parent="1022" relname="joint"/>
<group id="1025" type="multinuc" parent="1024" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="span" parent="1025" relname="joint"/>
<group id="1028" type="multinuc" parent="1024" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="span"/>
<group id="1031" type="multinuc" parent="1028" relname="joint"/>
<group id="1032" type="span" parent="1031" relname="joint"/>
<group id="1033" type="multinuc" parent="32" relname="elaboration"/>
<group id="1034" type="span" parent="1033" relname="joint"/>
<group id="1035" type="multinuc" parent="1031" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="36" relname="elaboration"/>
<group id="1038" type="multinuc" parent="1035" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="span"/>
<group id="1042" type="multinuc" parent="1039" relname="joint"/>
<group id="1043" type="multinuc" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="span"/>
<group id="1047" type="multinuc" parent="1043" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="joint"/>
<group id="1049" type="span" parent="1048" relname="sequence"/>
<group id="1050" type="span" parent="49" relname="purpose"/>
<group id="1051" type="span" parent="50" relname="elaboration"/>
<group id="1052" type="multinuc" parent="1048" relname="sequence"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="multinuc" parent="1052" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1054" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="joint"/>
<group id="1058" type="multinuc" parent="57" relname="means"/>
<group id="1059" type="multinuc" parent="1056" relname="joint"/>
<group id="1060" type="span" parent="1059" relname="joint"/>
<group id="1061" type="span" parent="1060" relname="span"/>
<group id="1062" type="multinuc" parent="1059" relname="joint"/>
<group id="1063" type="span" parent="1062" relname="joint"/>
<group id="1064" type="span" parent="1062" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="span"/>
<group id="1066" type="multinuc" parent="1065" relname="elaboration"/>
<group id="1067" type="span" parent="1066" relname="joint"/>
<group id="1068" type="multinuc" parent="68" relname="elaboration"/>
<group id="1069" type="multinuc" parent="1068" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="joint"/>
	</body>
</rst>
